Managing Fertility Care During Treatment Rescheduling

Abstract

Rescheduling fertility treatment presents unique clinical and psychosocial challenges, particularly in the context of unforeseen disruptions such as public health crises, resource limitations, or patient-specific medical complications. This review analyzes the epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, management approaches, recent advances, and guideline recommendations pertinent to fertility care during treatment rescheduling. Emphasis is placed on evidence-based, guideline-driven, and mechanism-oriented strategies to optimize outcomes, minimize risks, and facilitate patient-centered care for individuals and couples navigating altered timelines for reproductive interventions.

Introduction

Fertility care is inherently time-sensitive, with clinical outcomes closely linked to patient age, underlying etiology, and the timing of interventions. Unanticipated rescheduling whether due to institutional constraints, emergent comorbidities, or external factors such as pandemics can profoundly impact clinical decision-making and patient prognosis. Understanding the mechanisms by which delays affect reproductive potential, and the best practices for mitigating adverse effects, is essential for reproductive endocrinologists, gynecologists, and related healthcare professionals. This article synthesizes current evidence and expert guidance to support optimal management of fertility care during periods of treatment rescheduling.

Epidemiology / Disease Burden

Infertility affects up to 15% of reproductive-aged couples globally, with the demand for assisted reproductive technology (ART) rising steadily. Disruptions to fertility services, most notably observed during the COVID-19 pandemic, have led to widespread treatment delays impacting thousands of cycles annually. Studies highlight that even brief interruptions in fertility care may decrease the probability of live birth, particularly in women over 35 years or those with diminished ovarian reserve. The cumulative burden includes both diminished clinical outcomes and increased psychosocial distress among affected individuals and couples.

Pathophysiology

The biological basis for urgency in fertility care stems from the natural decline in gamete quality and quantity over time. Oocyte quantity diminishes inexorably with age, and oocyte aneuploidy rates rise, markedly reducing fecundity beyond age 35. Male fertility also declines, albeit more gradually, with increasing DNA fragmentation and reduced sperm motility. Treatment rescheduling exacerbates these age-dependent declines, and in certain cases (e.g., endometriosis, diminished ovarian reserve), delays may accelerate disease progression, further compromising reproductive potential.

Risk Factors

Major risk factors for adverse impact from treatment delays include advanced maternal age, diminished ovarian reserve (AMH <1.1 ng/mL, AFC <5), severe male factor infertility, and comorbid gynecologic conditions such as endometriosis or uterine fibroids. Other risks include prior suboptimal ART outcomes, polycystic ovary syndrome (PCOS) with oligo-anovulation, and patients with time-sensitive fertility preservation needs (e.g., those with impending gonadotoxic therapy).

Clinical Features

Clinical manifestations of delayed fertility care may be subtle yet significant. Women may present with progressive decrease in ovarian reserve, altered menstrual patterns, or worsening endometriosis-associated symptoms. Men may experience further deterioration in semen parameters. Psychosocial features include heightened anxiety, depressive symptoms, and relationship stress, which can independently affect reproductive outcomes. Timely assessment and counseling are thus critical components of ongoing care during periods of rescheduling.

Diagnosis

Assessment during rescheduling should include re-evaluation of ovarian reserve (AMH, AFC), semen analysis, and monitoring for interval development of new comorbidities. Where indicated, repeat imaging (transvaginal ultrasound, hysterosalpingography) may be required to assess for progression of uterine or adnexal disease. Psychosocial screening tools are recommended to identify individuals in need of support or mental health referral.

Treatment & Management

Management strategies should be individualized, prioritizing patients at highest risk for adverse outcomes from delays. Options include cycle monitoring, oocyte or embryo cryopreservation to mitigate against further decline, and pharmacologic suppression of endometriosis or PCOS symptoms. Telemedicine follow-up can support continuity of care and counseling. Coordination with multidisciplinary teams is essential, particularly for patients requiring fertility preservation prior to cancer therapy. Documentation of all clinical decisions and patient communications is critical for medico-legal and quality assurance purposes.

Recent Advances / Emerging Therapies

Recent advances include improved vitrification techniques for gamete and embryo cryopreservation, which offer high survival and clinical pregnancy rates even after prolonged storage. The development of at-home ovarian stimulation monitoring devices enables remote cycle tracking, facilitating safer and more flexible care during rescheduling. Additionally, research into ovarian rejuvenation and stem-cell-based therapies holds promise for mitigating the effects of age-related infertility, though these remain experimental.

Guideline Recommendations

Leading societies (ASRM, ESHRE, FIGO) recommend a tiered triage of fertility care during disruptions: urgent cases (e.g., fertility preservation prior to gonadotoxic therapy) should not be delayed, while elective ART may be rescheduled based on patient age and prognosis. Clear communication, informed consent regarding risks of delay, and psychological support are essential. Guidelines emphasize the need for up-to-date patient assessment prior to resuming treatment and encourage flexible care pathways incorporating remote monitoring and counseling.

Conclusion

Careful management of fertility treatment during periods of rescheduling is critical to optimizing clinical outcomes and supporting patient well-being. By integrating individualized risk assessment, evidence-based interventions, and multidisciplinary collaboration, clinicians can mitigate the adverse effects of treatment delays. Ongoing research and innovation continue to enhance the resilience of fertility care delivery in the face of evolving challenges, ensuring that patient-centered, high-quality reproductive medicine remains accessible despite unforeseen disruptions.